tiprankstipranks
Ultragenyx Pharmaceutical, Inc. (CH:UP0)
NASDAQ:UP0
Switzerland Market
UP0
Ultragenyx Pharmaceutical
RESEARCH TOOLSreports

Ultragenyx Pharmaceutical (UP0) Stock Forecast & Price Target

0 Followers
See the Price Targets and Ratings of:

UP0 Analyst Ratings

Strong Buy
15Ratings
Strong Buy
14 Buy
1 Hold
0 Sell
Based on 15 analysts giving stock ratings to
Ultragenyx
Pharmaceutical
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

UP0 Stock 12 Month Forecast

Average Price Target

$43.80
Based on 15 Wall Street analysts offering 12 month price targets for Ultragenyx Pharmaceutical in the last 3 months. The average price target is $43.80 with a high forecast of $77.67 and a low forecast of $21.04. The average price target represents a ― change from the last price of ―.
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
Highest Price Target$77.67Average Price Target$43.80Lowest Price Target$21.04
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
J.P. Morgan Analyst forecast on CH:UP0
Anupam Rama
J.P. Morgan
J.P. Morgan
CHF58.25
Buy
―
Reiterated
07/07/26
Ultragenyx: Favorable Risk-Reward Ahead of GTX-102 ASPIRE Readout, Analyst Reiterates Buy and $72 Price Target
RBC Capital Analyst forecast on CH:UP0
Luca Issi
RBC Capital
RBC Capital
CHF28.32→CHF32.36
Buy
―
Reiterated
07/07/26
Ultragenyx price target raised to $40 from $35 at RBC CapitalUltragenyx price target raised to $40 from $35 at RBC Capital
Canaccord Genuity Analyst forecast on CH:UP0
Whitney Ijem
Canaccord Genuity
Canaccord Genuity
CHF63.91
Buy
―
Reiterated
06/10/26
Analysts Offer Insights on Healthcare Companies: Ultragenyx Pharmaceutical (NASDAQ: RARE), Align Tech (NASDAQ: ALGN) and Smith & Nephew Snats (NYSE: SNN)
Cantor Fitzgerald Analyst forecast on CH:UP0
Kristen Kluska
Cantor Fitzgerald
Cantor Fitzgerald
CHF67.96→CHF77.67
Buy
―
Assigned
05/20/26
Analysts Offer Insights on Healthcare Companies: Belite Bio, Inc. ADR (NASDAQ: BLTE) and Ultragenyx Pharmaceutical (NASDAQ: RARE)
H.C. Wainwright Analyst forecast on CH:UP0
Ram Selvaraju
H.C. Wainwright
H.C. Wainwright
CHF40.45
Buy
―
Reiterated
05/11/26
Analysts Offer Insights on Healthcare Companies: Kodiak Sciences (NASDAQ: KOD), IN8bio (NASDAQ: INAB) and Ultragenyx Pharmaceutical (NASDAQ: RARE)
Evercore ISI Analyst forecast on CH:UP0
Gavin Clark-Gartner
Evercore ISI
Evercore ISI
CHF27.51→CHF26.7
Buy
―
Reiterated
05/11/26
Ultragenyx price target lowered to $33 from $34 at Evercore ISIUltragenyx price target lowered to $33 from $34 at Evercore ISI
Wedbush Analyst forecast on CH:UP0
Laura Chico
Wedbush
Wedbush
CHF21.84→CHF21.04
Hold
―
Reiterated
05/08/26
Wedbush Sticks to Their Hold Rating for Ultragenyx Pharmaceutical (RARE)
Guggenheim Analyst forecast on CH:UP0
Debjit Chattopadhyay
Guggenheim
Guggenheim
CHF42.07→CHF34.79
Buy
―
Reiterated
05/08/26
Ultragenyx price target lowered to $43 from $52 at GuggenheimUltragenyx price target lowered to $43 from $52 at Guggenheim
Piper Sandler Analyst forecast on CH:UP0
Allison Bratzel
Piper Sandler
Piper Sandler
CHF55.02
Buy
―
Reiterated
05/07/26
Ultragenyx Pharmaceutical (RARE) Gets a Buy from Piper Sandler
Morgan Stanley Analyst forecast on CH:UP0
Maxwell Skor
Morgan Stanley
Morgan Stanley
CHF54.21
Buy
―
Reiterated
05/06/26
Analysts Offer Insights on Healthcare Companies: Rhythm Pharmaceuticals (NASDAQ: RYTM), Henry Schein (NASDAQ: HSIC) and Ultragenyx Pharmaceutical (NASDAQ: RARE)
Barclays Analyst forecast on CH:UP0
Eliana Merle
Barclays
Barclays
CHF34.79
Buy
―
Reiterated
05/06/26
Barclays Keeps Their Buy Rating on Ultragenyx Pharmaceutical (RARE)
Wells Fargo Analyst forecast on CH:UP0
Benjamin Burnett
Wells Fargo
Wells Fargo
CHF36.41→CHF38.03
Buy
―
Reiterated
05/06/26
Ultragenyx Pharmaceutical (RARE) Receives a Buy from Wells Fargo
TD Cowen Analyst forecast on CH:UP0
Yaron Werber
TD Cowen
TD Cowen
CHF39.64
Buy
―
Reiterated
05/05/26
Analysts Offer Insights on Healthcare Companies: Alphatec Holdings (NASDAQ: ATEC) and Ultragenyx Pharmaceutical (NASDAQ: RARE)
Citi Analyst forecast on CH:UP0
Yigal Nochomovitz
Citi
Citi
CHF36.41
Buy
―
Reiterated
05/05/26
Analysts Have Conflicting Sentiments on These Healthcare Companies: Ultragenyx Pharmaceutical (NASDAQ: RARE), American Well (NYSE: AMWL) and Adaptive Biotechnologies (NASDAQ: ADPT)
Bank of America Securities Analyst forecast on CH:UP0
Tazeen Ahmad
Bank of America Securities
Bank of America Securities
―
Buy
―
Reiterated
04/16/26
Analysts' Top Healthcare Picks: RxSight (RXST), Ultragenyx Pharmaceutical (RARE)
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
J.P. Morgan Analyst forecast on CH:UP0
Anupam Rama
J.P. Morgan
J.P. Morgan
CHF58.25
Buy
―
Reiterated
07/07/26
Ultragenyx: Favorable Risk-Reward Ahead of GTX-102 ASPIRE Readout, Analyst Reiterates Buy and $72 Price Target
RBC Capital Analyst forecast on CH:UP0
Luca Issi
RBC Capital
RBC Capital
CHF28.32→CHF32.36
Buy
―
Reiterated
07/07/26
Ultragenyx price target raised to $40 from $35 at RBC CapitalUltragenyx price target raised to $40 from $35 at RBC Capital
Canaccord Genuity Analyst forecast on CH:UP0
Whitney Ijem
Canaccord Genuity
Canaccord Genuity
CHF63.91
Buy
―
Reiterated
06/10/26
Analysts Offer Insights on Healthcare Companies: Ultragenyx Pharmaceutical (NASDAQ: RARE), Align Tech (NASDAQ: ALGN) and Smith & Nephew Snats (NYSE: SNN)
Cantor Fitzgerald Analyst forecast on CH:UP0
Kristen Kluska
Cantor Fitzgerald
Cantor Fitzgerald
CHF67.96→CHF77.67
Buy
―
Assigned
05/20/26
Analysts Offer Insights on Healthcare Companies: Belite Bio, Inc. ADR (NASDAQ: BLTE) and Ultragenyx Pharmaceutical (NASDAQ: RARE)
H.C. Wainwright Analyst forecast on CH:UP0
Ram Selvaraju
H.C. Wainwright
H.C. Wainwright
CHF40.45
Buy
―
Reiterated
05/11/26
Analysts Offer Insights on Healthcare Companies: Kodiak Sciences (NASDAQ: KOD), IN8bio (NASDAQ: INAB) and Ultragenyx Pharmaceutical (NASDAQ: RARE)
Evercore ISI Analyst forecast on CH:UP0
Gavin Clark-Gartner
Evercore ISI
Evercore ISI
CHF27.51→CHF26.7
Buy
―
Reiterated
05/11/26
Ultragenyx price target lowered to $33 from $34 at Evercore ISIUltragenyx price target lowered to $33 from $34 at Evercore ISI
Wedbush Analyst forecast on CH:UP0
Laura Chico
Wedbush
Wedbush
CHF21.84→CHF21.04
Hold
―
Reiterated
05/08/26
Wedbush Sticks to Their Hold Rating for Ultragenyx Pharmaceutical (RARE)
Guggenheim Analyst forecast on CH:UP0
Debjit Chattopadhyay
Guggenheim
Guggenheim
CHF42.07→CHF34.79
Buy
―
Reiterated
05/08/26
Ultragenyx price target lowered to $43 from $52 at GuggenheimUltragenyx price target lowered to $43 from $52 at Guggenheim
Piper Sandler Analyst forecast on CH:UP0
Allison Bratzel
Piper Sandler
Piper Sandler
CHF55.02
Buy
―
Reiterated
05/07/26
Ultragenyx Pharmaceutical (RARE) Gets a Buy from Piper Sandler
Morgan Stanley Analyst forecast on CH:UP0
Maxwell Skor
Morgan Stanley
Morgan Stanley
CHF54.21
Buy
―
Reiterated
05/06/26
Analysts Offer Insights on Healthcare Companies: Rhythm Pharmaceuticals (NASDAQ: RYTM), Henry Schein (NASDAQ: HSIC) and Ultragenyx Pharmaceutical (NASDAQ: RARE)
Barclays Analyst forecast on CH:UP0
Eliana Merle
Barclays
Barclays
CHF34.79
Buy
―
Reiterated
05/06/26
Barclays Keeps Their Buy Rating on Ultragenyx Pharmaceutical (RARE)
Wells Fargo Analyst forecast on CH:UP0
Benjamin Burnett
Wells Fargo
Wells Fargo
CHF36.41→CHF38.03
Buy
―
Reiterated
05/06/26
Ultragenyx Pharmaceutical (RARE) Receives a Buy from Wells Fargo
TD Cowen Analyst forecast on CH:UP0
Yaron Werber
TD Cowen
TD Cowen
CHF39.64
Buy
―
Reiterated
05/05/26
Analysts Offer Insights on Healthcare Companies: Alphatec Holdings (NASDAQ: ATEC) and Ultragenyx Pharmaceutical (NASDAQ: RARE)
Citi Analyst forecast on CH:UP0
Yigal Nochomovitz
Citi
Citi
CHF36.41
Buy
―
Reiterated
05/05/26
Analysts Have Conflicting Sentiments on These Healthcare Companies: Ultragenyx Pharmaceutical (NASDAQ: RARE), American Well (NYSE: AMWL) and Adaptive Biotechnologies (NASDAQ: ADPT)
Bank of America Securities Analyst forecast on CH:UP0
Tazeen Ahmad
Bank of America Securities
Bank of America Securities
―
Buy
―
Reiterated
04/16/26
Analysts' Top Healthcare Picks: RxSight (RXST), Ultragenyx Pharmaceutical (RARE)
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
BBOTBridgeBio Oncology Therapeutics
AVBPArriVent BioPharma, Inc.
BTSGBrightSpring Health Services, Inc.
MLYSMineralys Therapeutics, Inc.
AMLXAmylyx Pharmaceuticals Inc
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Ultragenyx Pharmaceutical

3 Months
Whitney IjemCanaccord Genuity
Success Rate
10/16 ratings generated profit
63%
Average Return
+11.49%
Copying Whitney Ijem's trades and holding each position for 3 Months would result in 62.50% of your transactions generating a profit, with an average return of +11.49% per trade.
1 Year
Whitney IjemCanaccord Genuity
Success Rate
9/16 ratings generated profit
56%
Average Return
+7.41%
Copying Whitney Ijem's trades and holding each position for 1 Year would result in 56.25% of your transactions generating a profit, with an average return of +7.41% per trade.
2 Years
Luca IssiRBC Capital
Success Rate
8/17 ratings generated profit
47%
Average Return
+2.20%
Copying Luca Issi's trades and holding each position for 2 Years would result in 47.06% of your transactions generating a profit, with an average return of +2.20% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

UP0 Analyst Recommendation Trends

Rating
Mar 26
Apr 26
May 26
Jun 26
Jul 26
Strong Buy
30
20
18
16
13
Buy
7
6
3
3
3
Hold
3
2
2
1
1
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
40
28
23
20
17
In the current month, UP0 has received 16 Buy Ratings, 1 Hold Ratings, and 0 Sell Ratings. UP0 average Analyst price target in the past 3 months is 43.80.
Each month's total comprises the sum of three months' worth of ratings.

UP0 Financial Forecast

UP0 Earnings Forecast

Next quarter’s earnings estimate for UP0 is -$0.98 with a range of -$1.17 to -$0.63. The previous quarter’s EPS was -$1.48. UP0 beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.81% of the time in the same period. In the last calendar year UP0 has Performed in-line its overall industry.
Next quarter’s earnings estimate for UP0 is -$0.98 with a range of -$1.17 to -$0.63. The previous quarter’s EPS was -$1.48. UP0 beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.81% of the time in the same period. In the last calendar year UP0 has Performed in-line its overall industry.

UP0 Sales Forecast

Next quarter’s sales forecast for UP0 is $146.44M with a range of $112.96M to $162.66M. The previous quarter’s sales results were $109.37M. UP0 beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 48.70% of the time in the same period. In the last calendar year UP0 has Performed in-line its overall industry.
Next quarter’s sales forecast for UP0 is $146.44M with a range of $112.96M to $162.66M. The previous quarter’s sales results were $109.37M. UP0 beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 48.70% of the time in the same period. In the last calendar year UP0 has Performed in-line its overall industry.

UP0 Stock Forecast FAQ

What is CH:UP0’s average 12-month price target, according to analysts?
Based on analyst ratings, Ultragenyx Pharmaceutical, Inc.’s 12-month average price target is 43.80.
    What is CH:UP0’s upside potential, based on the analysts’ average price target?
    Currently there's no upside potential for CH:UP0, based on the analysts’ average price target.
    Can I see which stocks the top-ranking analysts are rating?
    Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
      How can I follow the stock ratings of top Wall Street analysts?
      Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
        Is Ultragenyx Pharmaceutical, Inc. a Buy, Sell or Hold?
        Ultragenyx Pharmaceutical, Inc. has a consensus rating of Strong Buy, which is based on 14 buy ratings, 1 hold ratings and 0 sell ratings.
          What is Ultragenyx Pharmaceutical, Inc.’s share price target?
          The average share price target for Ultragenyx Pharmaceutical, Inc. is 43.80. This is based on 15 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
          The highest analyst share price target is $77.67 ,and the lowest forecast is $21.04. The average share price target represents N/A Increase from the current price of N/A.
            What do analysts say about Ultragenyx Pharmaceutical, Inc.?
            Ultragenyx Pharmaceutical, Inc.’s analyst rating consensus is a Strong Buy. This is based on the ratings of 15 Wall Streets Analysts.
              How can I buy shares of Ultragenyx Pharmaceutical, Inc.?
              To buy shares of CH:UP0, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.